[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343504-105":59,"doc-detail-343504-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antibody-targeted-t-cells-and-natural-killer-cells-for-cancer-immunotherapy","Antibody-targeted T cells and natural killer cells for cancer immunotherapy","","Adoptive cell cancer therapies re-engineer patient immune cells to generate anti-cancer activity, yet genetic engineering of CAR T and NK cells can be laborious, costly, inefficient, and prone to severe toxicities from over-proliferation. This study evaluates a non-genetic strategy that anchors antibodies to activated T and NK cells via metabolic glycoengineering and SPAAC. Antibody-conjugated cells home to tumors expressing GM3 ganglioside and lyse antigen-positive cancer cells while minimizing off-target toxicities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antibody-targeted-t-cells-and-natural-killer-cells-for-cancer-immunotherapy/343504/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antibody-targeted-t-cells-and-natural-killer-cells-for-cancer-immunotherapy/343504.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in adoptive cell cancer therapy?","Question",{"text":112,"@type":113},"Genetic engineering of CAR T and NK cells can be inefficient, expensive, and may cause severe toxicities when engineered cells over-proliferate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are antibodies attached to T and NK cells in this work?",{"text":117,"@type":113},"Activated T and NK cells are metabolically glycoengineered to introduce azide groups, then covalently linked to a dibenzocyclooctyne-modified antibody using the strain-promoted alkyne azide cycloaddition (SPAAC).",{"name":119,"@type":110,"acceptedAnswer":120},"Which tumors can be targeted and what antigen is used for specificity?",{"text":121,"@type":113},"The engineered cells target tumors expressing the xenoantigen GM3 ganglioside (N-glycolyl neuraminic acid GM3), recognized by the 14F7hT antibody, enabling antigen-positive cancer cell killing with reduced off-target toxicities.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343504,1790158590,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Sutherland et al.  \nJournal of Nanobiotechnology [https://doi.org/10.1186/s12951](https://doi.org/10.1186/s12951)  \n(2024) 22:640 -024-02898-3  \nJournal of Nanobiotechnology  \n RESEARCH Open Access  \nAntibody-targeted T cells and natural killer cells for cancer immunotherapy  \nAshley R. Sutherland 1, Brijesh Parlekar2, David W. Livingstone2, Andrés X. Medina3, Wendy Bernhard3, Tays Hernández García4, John DeCoteau3 and C. Ronald Geyer3*  \nAbstract  \nBackground Adoptive cell cancer therapies aim to re-engineer a patient’s immune cells to mount an anti-cancer response. Chimeric antigen receptor T and natural killer cells have been engineered and proved successful in treating some cancers; however, the genetic methods for engineering are laborious, expensive, and inefficient and can cause severe toxicities when they over-proliferate.  \nResults We examined whether the cell-killing capacity of activated T and NK cells could be targeted to cancer cells by anchoring antibodies to their cell surface. Using metabolic glycoengineering to introduce azide moieties to the cellular surface, we covalently attached a dibenzocyclooctyne-modified antibody using the strain-promoted alkyne azide cycloaddition reaction, creating antibody-conjugated T and NK cells. We targeted the immune cells to tumors possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14F7hT antibody. These activated T and NK cells are “armed” with tumour-homing capabilities that specifically lyses antigen-positive cancer cells without off-target toxicities. Moreover, when exposed to target cells, 14F7hT-conjugated T cells that are not preactivated exhibit increased perforin, granzyme, CD69, and CD25 expression and specific cell killing. Conclusions This research shows the potential for a non-genetic method for redirecting cytotoxic immune cells as a feasible and effective approach for tumor-targeted cell immunotherapy.  \n*Correspondence:  \nC. Ronald Geyer  \n[clg595@mail.usask.ca](clg595@mail.usask.ca)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nSutherland et al. Journal of Nanobiotechnology (2024) 22:640 Page 2 of 13  \n\n| Graphical Abstract |\n| --- |\n| |\n|  |\n\nIntroduction  \nCell membrane engineering has a wide range of applications in both basic and applied science, from the study of cell signaling and cell–cell interactions to the recent advancement of cell therapies. Chimeric antigen receptor (CAR) T and NK cell therapies rely on the expression and engineering of cancer-antigen binding chimeric receptors on the surface of immune cells through genetic manipulation [1, 2]. CAR cell therapies have shown remarkable success in treating a variety of hematopoietic cancers; however, rapid expansion of engineered cells can induce severe cytokine release and neurotoxic side effects [3–5]. Furthermore, the incorporation of CAR in immune cells through viral vectors has constraints such as technical difficulties and safety concerns [6, 7]. These include heterogenous CAR expre","cbCaioZGwjcDmAYE","https://ap.wps.com/l/cbCaioZGwjcDmAYE","pdf",1603045,13,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Introduction\n## Cell membrane engineering and CAR therapies\n## SPAAC and metabolic glycoengineering\n## Study objective and target antibody (14F7hT)","[{\"question\":\"What problem does the study address in adoptive cell cancer therapy?\",\"answer\":\"Genetic engineering of CAR T and NK cells can be inefficient, expensive, and may cause severe toxicities when engineered cells over-proliferate.\"},{\"question\":\"How are antibodies attached to T and NK cells in this work?\",\"answer\":\"Activated T and NK cells are metabolically glycoengineered to introduce azide groups, then covalently linked to a dibenzocyclooctyne-modified antibody using the strain-promoted alkyne azide cycloaddition (SPAAC).\"},{\"question\":\"Which tumors can be targeted and what antigen is used for specificity?\",\"answer\":\"The engineered cells target tumors expressing the xenoantigen GM3 ganglioside (N-glycolyl neuraminic acid GM3), recognized by the 14F7hT antibody, enabling antigen-positive cancer cell killing with reduced off-target toxicities.\"}]","Antibody-targeted T cells and natural killer cells for cancer immunotherapy | PDF",1790051331,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c450410f6d9f6d51cac87cdcbb0682d.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42c208b62f8b3bcb262efde579f7687a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59c09a86950375f7573b5c233e7f91df.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7274e12e838550671d206173c82c4999.webp",980,1301]